NCT03126214View on ClinicalTrials.gov

Improving Stroke Prevention in Atrial Fibrillation Through Pharmacist Prescribing

PHASE4CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

July 1, 2022

Study Completion Date

December 1, 2023

Conditions
Atrial FibrillationStroke
Interventions
DRUG

Anticoagulants

Anticoagulant therapy will be initiated/titrated in patients with atrial fibrillation in accordance with the Canadian Cardiovascular Society Guidelines for Atrial Fibrillation.

Trial Locations (1)

T6G 2E1

University of Alberta, Edmonton

All Listed Sponsors
collaborator

Heart and Stroke Foundation of Canada

OTHER

collaborator

Canadian Stroke Prevention Intervention Network

OTHER

lead

University of Alberta

OTHER

NCT03126214 - Improving Stroke Prevention in Atrial Fibrillation Through Pharmacist Prescribing | Biotech Hunter | Biotech Hunter